Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.08)
# 1,199
Out of 5,146 analysts
102
Total ratings
37.96%
Success rate
3.34%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Maintains: Buy | $11 → $8 | $3.24 | +146.91% | 9 | Feb 27, 2026 | |
| PYPD PolyPid | Reiterates: Buy | $13 | $4.22 | +208.06% | 5 | Feb 11, 2026 | |
| CRDL Cardiol Therapeutics | Reiterates: Buy | $9 | $1.07 | +741.12% | 3 | Feb 10, 2026 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Buy | $20 | $14.41 | +38.79% | 3 | Feb 10, 2026 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $29 | $5.87 | +394.04% | 2 | Feb 3, 2026 | |
| CRMD CorMedix | Maintains: Buy | $18 → $13 | $7.35 | +76.87% | 5 | Jan 23, 2026 | |
| HRTX Heron Therapeutics | Reiterates: Buy | $6 | $1.20 | +400.00% | 3 | Jan 9, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $10 | $6.74 | +48.37% | 4 | Jan 9, 2026 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $46 → $60 | $44.22 | +35.69% | 8 | Jan 9, 2026 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $21 | $11.52 | +82.29% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $1.38 | +697.10% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $8.18 | +46.70% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $40 | $11.55 | +246.32% | 4 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.72 | +365.12% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $23.40 | +156.41% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.62 | +393.83% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.20 | +733.33% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $77.15 | +56.84% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $10.94 | +64.53% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $8.71 | +49.25% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.73 | +153.70% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.54 | +175.59% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.09 | +186.03% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.93 | +436.94% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $2.53 | +7,805.14% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $11.10 | +44.14% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $8.12 | +5,503.45% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $21.07 | +180.02% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $188.97 | -4.75% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.66 | +8,170.68% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $30.73 | +4.13% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $0.98 | +2,244,797.96% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $11.15 | +348.43% | 1 | Jul 12, 2018 |
MannKind
Feb 27, 2026
Maintains: Buy
Price Target: $11 → $8
Current: $3.24
Upside: +146.91%
PolyPid
Feb 11, 2026
Reiterates: Buy
Price Target: $13
Current: $4.22
Upside: +208.06%
Cardiol Therapeutics
Feb 10, 2026
Reiterates: Buy
Price Target: $9
Current: $1.07
Upside: +741.12%
Enanta Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $20
Current: $14.41
Upside: +38.79%
Sagimet Biosciences
Feb 3, 2026
Reiterates: Buy
Price Target: $29
Current: $5.87
Upside: +394.04%
CorMedix
Jan 23, 2026
Maintains: Buy
Price Target: $18 → $13
Current: $7.35
Upside: +76.87%
Heron Therapeutics
Jan 9, 2026
Reiterates: Buy
Price Target: $6
Current: $1.20
Upside: +400.00%
Xeris Biopharma Holdings
Jan 9, 2026
Reiterates: Buy
Price Target: $10
Current: $6.74
Upside: +48.37%
Collegium Pharmaceutical
Jan 9, 2026
Reiterates: Buy
Price Target: $46 → $60
Current: $44.22
Upside: +35.69%
Trevi Therapeutics
Jan 9, 2026
Reiterates: Buy
Price Target: $21
Current: $11.52
Upside: +82.29%
Jan 9, 2026
Reiterates: Buy
Price Target: $11
Current: $1.38
Upside: +697.10%
Jan 9, 2026
Reiterates: Buy
Price Target: $12
Current: $8.18
Upside: +46.70%
Jan 8, 2026
Maintains: Buy
Price Target: $20 → $40
Current: $11.55
Upside: +246.32%
Jan 6, 2026
Reiterates: Buy
Price Target: $8
Current: $1.72
Upside: +365.12%
Dec 3, 2025
Initiates: Buy
Price Target: $60
Current: $23.40
Upside: +156.41%
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $1.62
Upside: +393.83%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.20
Upside: +733.33%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $77.15
Upside: +56.84%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $10.94
Upside: +64.53%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $8.71
Upside: +49.25%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.73
Upside: +153.70%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.54
Upside: +175.59%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $9.09
Upside: +186.03%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.93
Upside: +436.94%
Nov 14, 2024
Initiates: Buy
Price Target: $200
Current: $2.53
Upside: +7,805.14%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $11.10
Upside: +44.14%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $8.12
Upside: +5,503.45%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $21.07
Upside: +180.02%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $188.97
Upside: -4.75%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.66
Upside: +8,170.68%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $30.73
Upside: +4.13%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $0.98
Upside: +2,244,797.96%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $11.15
Upside: +348.43%